Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. Postal Service can continue to deliver prescription abortion medication - DOJ

Published 01/03/2023, 07:31 PM
Updated 01/04/2023, 01:57 PM
© Reuters. FILE PHOTO: Bottles of Misoprostol, the second medication used in a medical abortion, lay unused in a storage bin at a Houston abortion clinic which stopped providing abortions when the U.S. Supreme Court overturned Roe v. Wade, in Texas, U.S., July 7, 20

By David Shepardson

WASHINGTON (Reuters) -The U.S. Postal Service (USPS) can continue to deliver prescription abortion medication despite a June 2022 Supreme Court ruling that overturned a landmark abortion rights decision, the Justice Department said on Tuesday.

The department's Office of Legal Counsel said in an opinion sought by USPS that the mailing of mifepristone and misoprostol, commonly used to terminate pregnancies, did not violate an 1873 law known as the Comstock Act.

USPS said in a statement the opinion "confirms that the Comstock Act does not require the Postal Service to change our current practice, which has been to consider packages containing mifepristone and misoprostol to be mailable under federal law in the same manner as other prescription drugs." 

Mifepristone is a prescription drug approved by the Food and Drug Administration (FDA) to induce an abortion up to 10 weeks into a pregnancy. It must be followed by a second drug, misoprostol. Both drugs also have other uses.

A Justice Department spokesman declined to comment on the opinion.

The FDA in December 2021 permanently eased some restrictions on the medications, allowing them to be sent by mail rather than restricting them to in-person dispensing.

USPS said it took no position on abortion policy at either the federal or state level and noted the Justice Department opinion "specifies that the mailing of those drugs to a particular jurisdiction that may significantly restrict access to an abortion is not a sufficient basis" for the USPS to refuse to deliver them.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

USPS said the Justice Department concurred with its "determination that under the doctrine of intergovernmental immunity, any state laws that may apply to the shipment of those prescription drugs cannot be applied to Postal Service employees who are complying with their duties under federal law."

The Supreme Court's decision overturning the landmark 1973 Roe v. Wade ruling that recognized women's constitutional right to abortion put a spotlight on abortion by medication, which accounts for more than half of U.S. abortions.

A Dutch supplier of abortion pills by mail saw demand surge in the wake of the decision, which allowed more than 20 states to begin enforcing new restrictions on abortion.

Restrictions on the abortion medication lifted in 2021 had been in place since the FDA had approved the drug in 2000. They had been lifted temporarily earlier in 2021 due to the COVID-19 pandemic, enabling women to consult healthcare providers by telemedicine and receive the pills by mail.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.